Evidence mapPaperPMID 42589676Full record

ArticleInternational journal of molecular sciences2026

Acetyl L-Carnitine Nanoparticles Modulate Neuronal and Inflammatory Responses in In Vitro Cell Model.

Alessia Mariano, Benedetta Brugnoli, Iolanda Francolini, Sergio Ammendola, Anna Scotto d'Abusco

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alessia MarianoDepartment of Biochemical Sciences, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0002-9569-8952
Benedetta BrugnoliDepartment of Chemistry, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0002-9419-2829
Iolanda FrancoliniDepartment of Chemistry, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0002-0180-2334
Sergio AmmendolaAmbiotec di Sergio Ammendola, Via Appia Nord 47, 04012 Cisterna di Latina, Italy.ORCID 0000-0001-9452-2456
Anna Scotto d'AbuscoDepartment of Biochemical Sciences, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0002-3323-6015

Funding

Sapienza University of Rome AR2241906D527AF4Sapienza University of Rome RP125199A92791C5
6 · The paper itself

Abstract

Acetyl L-carnitine is an ester of the trimethylated amino acid L-carnitine with well-documented neuroprotective properties. Despite its ability to cross the blood-brain barrier, acetyl L-carnitine requires high and repeated doses to achieve and maintain therapeutic concentrations in the central nervous system. To overcome these limitations, nanotechnology-based delivery systems have emerged as a promising strategy to improve drug bioavailability, targeting, and therapeutic efficacy. In this study, we evaluated the efficacy of nanoparticle-based formulations of acetyl L-carnitine in comparison with its conventional bulk form using in vitro cultures of SH-SY5Y neuroblastoma cell line. The ALC nanoparticles were produced through an organic solvent-free mechanical ball milling process employing a planetary ball mill. The dimension and stability of the nanoparticles were analyzed by Dynamic Light Scattering and Thermogravimetric Analysis. The biological effects were evaluated using quantitative Real Time-Polymerase Chain Reaction, Enzyme-linked Immunosorbent Assay and immunofluorescence experiments. ALC nanoparticles, at low concentration of nanoparticles compared to the non-nanoparticle form, were able to decrease the alarmin S100B release, pro-inflammatory interleukin mRNA and protein expression as well as p65 activation, confirming their involvement in NF-κB pathway. Moreover, it was able to stimulate the nerve growth factor release and to increase intracellular Ca

Indexed as

AcetylcarnitineInflammationNanoparticlesNeuronsNeuroprotective AgentsCell Line, TumorHumansNF-kappa BS100 Calcium Binding Protein beta SubunitAcetylcarnitineNeuroprotective AgentsNF-kappa BS100 Calcium Binding Protein beta Subunitacetyl L-carnitinedrug deliverynanoparticlesnerve growth factorneuroprotectionNF-κB pathwayS100B

Identifiers

PMID42589676
PMCPMC13466921

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.